GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Covidien PLC (FRA:6COP) » Definitions » Change In Payables And Accrued Expense

Covidien (FRA:6COP) Change In Payables And Accrued Expense : €-345 Mil (TTM As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Covidien Change In Payables And Accrued Expense?

Covidien's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2014 was €-260 Mil. It means Covidien's Accounts Payable & Accrued Expense declined by €260 Mil from Sep. 2014 to Dec. 2014 .

Covidien's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2014 was €-293 Mil. It means Covidien's Accounts Payable & Accrued Expense declined by €293 Mil from Sep. 2013 to Sep. 2014 .


Covidien Change In Payables And Accrued Expense Historical Data

The historical data trend for Covidien's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covidien Change In Payables And Accrued Expense Chart

Covidien Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.34 -266.81 62.86 95.00 -293.33

Covidien Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.80 224.13 -405.54 95.45 -259.52

Covidien Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-345 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Covidien Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Covidien's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Covidien (FRA:6COP) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.

Covidien (FRA:6COP) Headlines

No Headlines